112 related articles for article (PubMed ID: 3857643)
1. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
2. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
[TBL] [Abstract][Full Text] [Related]
3. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Hock CE; Lefer AM
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
[TBL] [Abstract][Full Text] [Related]
4. Reduction in myocardial neutrophil accumulation and infarct size following administration of thromboxane inhibitor U-63,557A.
Wargovich TJ; Mehta J; Nichols WW; Ward MB; Lawson D; Franzini D; Conti CR
Am Heart J; 1987 Nov; 114(5):1078-85. PubMed ID: 2960223
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions and myocardial infarct size in rat.
Kumar C; Singh M
Eur J Pharmacol; 1985 Feb; 109(1):117-20. PubMed ID: 4039668
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effect of a thromboxane synthetase inhibitor in traumatic shock.
Hock CE; Lefer AM
Circ Shock; 1984; 14(3):159-68. PubMed ID: 6542462
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Ito T; Toki Y; Hieda N; Okumura K; Hashimoto H; Ogawa K; Satake T
Jpn Circ J; 1989 Sep; 53(9):1115-21. PubMed ID: 2513429
[TBL] [Abstract][Full Text] [Related]
8. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.
Hock CE; Ribeiro LG; Lefer AM
Am Heart J; 1985 Feb; 109(2):222-8. PubMed ID: 2981461
[TBL] [Abstract][Full Text] [Related]
9. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Spignoli G; Caputi AP
Pharmacology; 1993 Sep; 47(3):167-75. PubMed ID: 8415867
[TBL] [Abstract][Full Text] [Related]
10. Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
Bitterman H; Lefer DJ; Lefer AM
Proc Soc Exp Biol Med; 1987 Jul; 185(3):262-6. PubMed ID: 3037554
[TBL] [Abstract][Full Text] [Related]
11. Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction.
Tada M; Hoshida S; Kuzuya T; Inoue M; Minamino T; Abe H
Int J Cardiol; 1985 Jul; 8(3):301-12. PubMed ID: 4040500
[TBL] [Abstract][Full Text] [Related]
12. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor.
Burke SE; Lefer AM; Smith GM; Smith JB
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6681711
[TBL] [Abstract][Full Text] [Related]
13. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyclooxygenase and thromboxane synthetase inhibition on furosemide-stimulated plasma renin activity.
Datar S; McCauley FA; Wilson TW
Can J Physiol Pharmacol; 1987 Jan; 65(1):80-3. PubMed ID: 3105853
[TBL] [Abstract][Full Text] [Related]
15. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
[TBL] [Abstract][Full Text] [Related]
16. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
Hock CE; Brezinski ME; Lefer AM
Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
[TBL] [Abstract][Full Text] [Related]
17. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Faggiotto A; Caputi AP
Agents Actions; 1993 Jul; 39(3-4):143-9. PubMed ID: 8304242
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Tsuchida A; Miura T; Ogawa T; Iwamoto T; Shimamoto K; Iimura O
Jpn Circ J; 1991 Feb; 55(2):174-83. PubMed ID: 2020088
[TBL] [Abstract][Full Text] [Related]
19. The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models.
O'Connor KM; Friehling TD; Kowey PR
Am Heart J; 1989 Apr; 117(4):848-53. PubMed ID: 2929400
[TBL] [Abstract][Full Text] [Related]
20. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia.
Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
